AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04067804 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dynamic Adaptation Process
Description: The Dynamic Adaptation Process draws from implementation science frameworks and methods, including the Exploration, Preparation, Implementation, and Sustainment model, to organize planning and implementation activities. The Dynamic Adaptation Process is a structured methodology designed to integrate new interventions within complex systems, such as schools.
Study NCT02264327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing Simulator (SIM)
Description: The interactive, case-based, multiplayer web-based game allows service providers to deepen their skills in Motivational Interviewing (MI), a widely recognized evidence-based practice that supports people to make positive behavior changes related to health, wellness, mental illness, and addiction.The SIM will have three arenas for play, so that users can practice more advanced MI skills and include: Single Player, Two Player, and Advanced Free play. The SIM is equipped with multiple story-lines and characters to keep learners engaged over time and to provide practice on diverse case scenarios, making the Sim relevant to a wide audience. Lastly the SIM will provide an opportunity for feedback from peers and MI experts.
Study NCT02264327 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing eBook (eBook)
Description: The Phase I research team developed a 69-page eBook as a credible online comparator that presents information comparable to that included in the Sim, but without the interactive, role-playing, peer learning functionalities embodied in the Sim. Developed in Hyperlink Markup Language, the eBook presented MI skills, followed by transcripts of effective and not-effective samples of MI from the Sim itself. The e-Book includes the story-lines along with sample dialogue and expert feedback on MI skills.
Study NCT02264327 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing Training (MI Training)
Description: The training intervention consists of a free two-day standardized Motivational Interviewing (MI) training provided by experienced MI trainers.
Study NCT02264327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing Training (MI Training)
Description: The training intervention consists of a free two-day standardized Motivational Interviewing (MI) training provided by experienced MI trainers.
Study NCT00738387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA404
Description: 1800 mg/m2 of ASA404 i.v. on day 1 of each 21 day cycle
Study NCT01931163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Study NCT00738387 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo i.v. on day 1 of each 21 day cycle
Study NCT00738387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 75 mg/m2 of docetaxel intravenous (IV) an hour for 1st 6 cycles; cycle: every 21 days
Study NCT04678388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference drug
Description: 1 Cap., single oral administration under fasting condition
Study NCT01641367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs)
Description: LPV/r and ATV/r were the preferred bPIs for second-line ART. TDF + (3TC or FTC) or AZT + 3TC were the most frequent NRTI backbones. Cohort A did not include any of the new drugs; therefore, it is distinct from Cohorts B, C, and D.
Study NCT01641367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & available
Description: For Cohort D, in many situations a participant received the same regimen that patients are getting in Cohorts B and C if that was the best combination that can be obtained according to his/her resistance profile and drug availability (as for many countries there were no further drug options beyond the available study drugs).
Study NCT04678388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug 1
Description: 1 Tab., single oral administration under fasting condition
Study NCT04678388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug 2
Description: 1 Tab., single oral administration under fasting condition
Study NCT00738387 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: docetaxel
Description: 75 mg/m2 of docetaxel intravenous (IV) an hour for 1st 6 cycles; cycle: every 21 days
Study NCT01532401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sodium chloride
Description: sodium chloride 500mg
Study NCT04028141 — intervention group
Intervention type: DRUG
Intervention: Procedural sedation with ketofol in a 1 on 4 ratio
Description: The participant was brought to a zone where advanced life support could be optimally administered and where all necessary drugs and materials for treatment of complications are present. Oxygen saturation, continuous electrocardiogram, intermittent blood pressure measurement (every 2 minutes) and capnography were applied. A 20 gauge intravenous line was inserted. The participant was placed in semi-recumbent position and was given oxygen for at least 3 minutes through a non-rebreather mask unless contra-indications applied.~Ketofol 1 on 4 was prepared by mixing 1ml of ketamine (50mg) and 20ml of propofol (200mg) in a single syringe. It was administrated as a loading dose of 1ml/10kg, corresponding to 0,952mg/kg propofol and 0,238mg/kg ketamine, and followed by titration in aliquots of 0,5ml/10kg every 1 to 2 minutes until desired depth of sedation was achieved, and then every 3-5 minutes to retain the desired depth of sedation. The loading dose was halved if above 65 years.
Study NCT01641367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SOC adherence versus SOC+CPI adherence
Description: * not participating in the adherence randomization; OR~* randomized to SOC adherence; OR~* randomized to SOC+CPI adherence.
Study NCT01782781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine, ketorelac and epinephrine
Description: Active group
Study NCT01532401 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Methylcellulose crystalline
Description: Methylcellulose 37 ml
Study NCT01683396 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for subcutaneous injection
Study NCT01683396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gevokizumab
Description: Solution for subcutaneous injection
Study NCT00423878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Continued treatment with the medication risperidone for schizophrenia for up to 6 months in study
Study NCT03482492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Tramadol iv
Study NCT01782781 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group
Study NCT02607514 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: hyperthermic yoga
Description: heated yoga, 90-minutes
Study NCT02607514 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hyperthermic yoga
Description: heated yoga, 90-minutes
Study NCT01528605 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: zeaxanthin plus lutein
Description: one gelatine capsule containing 10 mg lutein and 15 mg zeaxanthin per day, for 48 weeks
Study NCT00136149 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate implants
Description: Immediate implants are used.
Study NCT02795728 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of the GIC based sealant
Description: Application of the GIC based sealant was carried out according to the manufacturer's instructions.
Study NCT02795728 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resin based sealant
Description: Application of the resin based sealant on the occlusal surfaces was carried out as per the manufacturer s recommendations.
Study NCT03221595 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Operative
Description: This operation involves reducing and providing rigid fixation of displaced rib fractures with permanent plates or splints
Study NCT04724954 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rehabilitation Therapy on Experimental Robotic Table and standard of care
Description: Experimental group will receive VR game-based rehabilitation therapy through Bright Cloud's proprietary device, called BrightArm Compact (BAC). They will also receive Standard of Care rehabilitation
Study NCT04724954 — intervention group
Intervention type: GENETIC
Group type: SHAM_COMPARATOR
Intervention: Rehabilitation Therapy as part of Standard of Care (Control)
Description: Control group will receive Standard of Care training only
Study NCT04632251 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SENSEI®
Description: SENSEI® laparoscopic tethered gamma probe is an intra-operative laparoscopic gamma probe system
Study NCT03002051 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS-guided drainage
Description: * Ultrasonographic evaluation of the lesion by linear echoendoscope and positioning for transenteric puncture in shortest distance between enteric wall and the target lumen for drainage.~* EUS-guided transenteric puncture by using a 19-gauge needle followed by placement of a 0.035 or 0.025-inch guidewire into the target lumen.~* After the needle is removed in remaining the guidewire, the tract is dilated over the guidewire by using bougie dilator or needle type cystotome (Endoflex, Voerde, Germany). And then, the tract may be more dilated by using balloon catheter (4-mm).~* After dilation of the tract, stent delivery system is inserted over the guidewire into the target lumen.~* After complete deployment of the distal flange under EUS and fluoroscopic guidance into the target lumen, proximal retraction of the delivery system until the blue mark on the handle of the introducer is seen. And then, the proximal flange is deployed slowly under endoscopic guidance.
Study NCT00769847 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic strip craniectomy
Description: Surgery
Study NCT00688480 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule, orally for 9 months
Study NCT00688480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Allopurinol 300 mg once/day orally, 9 months
Study NCT00994448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion SR 150mg tabs
Description: Bupropion SR 150mg tabs (Zyban) twice daily
Study NCT00994448 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: One placebo tablet twice daily
Study NCT04155515 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: TG-2349
Description: TG-2349 400mg
Study NCT04155515 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: DAG181
Description: DAG181 200mg
Study NCT04155515 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ribavirin
Description: Ribavirin 1000mg/1200mg
Study NCT02759120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antimicrobial therapy: Co-trimoxazole or Doxycycline
Description: 160mg trimethoprim/800mg sulfamethoxazole (double strength co-trimoxazole) twice daily plus folic acid 5 mg daily OR doxycycline 100mg once daily if weight \< 50 kilograms or 100mg twice daily if weight > 50 kilograms for up to 36 months
Study NCT02759120 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention: Standard of Care
Description: Standard of care
Study NCT04415606 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QuikClot Control+
Description: Non-absorbable, sterile, X-ray detectable non-woven dressing impregnated with kaolin.
Study NCT04415606 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: QuikClot Control+
Description: Non-absorbable, sterile, X-ray detectable non-woven dressing impregnated with kaolin.
Study NCT00937417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study NCT00937417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vandetanib
Study NCT00937417 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: proteomic profiling
Study NCT00937417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT00937417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study NCT02779842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone (BAY 987517)
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. formulation number SR15-39-Z12-002.
Study NCT04653779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evogliptin 5mg/Metformin 1000mg
Description: Size reduction of a tablet formulation
Study NCT02509065 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bionic Pancreas
Description: Participant wears the bionic pancreas, including an insulin and/or glucagon pump depending on which arm they are in. The 100 mg/dl arm for type 1 diabetes patients will deliver insulin and glucagon. The 100 mg/dl arm for type 2 diabetes patients will deliver just insulin. The 115 mg/dl arm will deliver insulin and glucagon. The 120 mg/dl arm will deliver just insulin. The 145 mg/dl arm will deliver just insulin. The 130 mg/dl and 110 mg/dl arms will deliver insulin and placebo, or insulin and glucagon, and will be double blinded.
Study NCT05453318 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treatment of cervical neoplasia by thermal ablation
Description: Women screened for cervical cancer by VIA presenting lesions eligible for ablative treatment were treated by thermal ablation. The treatment consisted in applying the probe on the lesion for 45 seconds at 100 degrees Celsius, with one to up to five applications depending on the lesion size. Following treatment, women were inquired about the pain level during the procedure, their satisfaction level of the procedure and whether they would recommend this treatment to their relatives. Women had a follow-up visit at 6 weeks to assess any complication of the procedure. Women were rescreened at 12 months, to evaluate the cure rate and any long-term adverse events.
Study NCT01682876 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: MenACWY-CRM
Description: The investigational meningococcal (groups A, C, Y, and W-135 vaccine) oligosaccharide diphtheria CRM197 conjugate vaccine (MenACWY-CRM) was administered intramuscularly in the nondominant arm
Study NCT01682876 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACWY-CRM
Description: The investigational meningococcal (groups A, C, Y, and W-135 vaccine) oligosaccharide diphtheria CRM197 conjugate vaccine (MenACWY-CRM) was administered intramuscularly in the nondominant arm
Study NCT02567331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Participants will receive 1250 mg/m\^2 capecitabine administered twice daily as oral tablets for 14 days followed by a 7 day rest period for up to 6 treatment cycles.
Study NCT01617343 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hemifield eye patching (HEP) + optokinetic stimulation (OKS)
Description: Patients in this arm will wear standard spectacle frames containing noncorrective lenses to which right half-field patches are attached (hemifield eye patching, HEP). In case of patients already wearing prescribed glasses, the patches will be attached to their own glasses. The glasses will be worn all-day for the duration of the treatment phase (seven days) and only be removed for sleeping and face cleaning as well as for the duration of the daily OKS treatment sessions.~Furthermore these patients will receive daily sessions (20 minutes) of optokinetic stimulation (OKS). Therefore patients will be seated in front of a widescreen monitor, watching a black background with a pattern of various objects (size 1°), which coherently and continuously move to the left at a velocity of 10 °/s.
Study NCT03797781 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower limb immobilisation (leg brace) with varying levels of protein intake
Description: Single leg immobilisation via leg brace and crutches, the groups have different amounts of protein intake
Study NCT01546311 — intervention group
Intervention type: DEVICE
Intervention: Pro Active Dynamic Accommodating Socket
Description: Socket with bladders that instantaneously adjusts to volume fluctuations in the residual limb
Study NCT00423878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Continued treatment with the medication olanzapine for schizophrenia for up to 6 months in study
Study NCT00423878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: Continued treatment with the medication quetiapine for schizophrenia for up to 6 months in study
Study NCT02509065 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participant cares for their diabetes according to their usual practice, with blinded CGM monitoring. No medication will be administered by the study in this intervention.
Study NCT01080794 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Description: DLPFC Active rTMS: Each treatment will consist of 2000 stimuli (50 X 4-second trains of 40 stimuli at 10 Hz, administered every 30 seconds for 25 minutes). Stimulus intensity for the first and second trains will be 80 and 90 percent of motor evoked potential (MEP), respectively. If no adverse effects are observed following each of the first two trains, then the subsequent trains will be given at MEP threshold.~M1 Active rTMS: Stimulation will be applied one side at a time, to the motor cortex site at 90 percent of each subject's motor threshold intensity, and at a frequency of 10 Hz with 1000 stimuli per side (25 X 8-second trains of 40 stimuli).~Sham rTMS: Patients from all four centers randomized to receive sham treatment will undergo the same procedures used in patients receiving active rTMS.
Study NCT01080794 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Description: DLPFC Active rTMS: Each treatment will consist of 2000 stimuli (50 X 4-second trains of 40 stimuli at 10 Hz, administered every 30 seconds for 25 minutes). Stimulus intensity for the first and second trains will be 80 and 90 percent of motor evoked potential (MEP), respectively. If no adverse effects are observed following each of the first two trains, then the subsequent trains will be given at MEP threshold.~M1 Active rTMS: Stimulation will be applied one side at a time, to the motor cortex site at 90 percent of each subject's motor threshold intensity, and at a frequency of 10 Hz with 1000 stimuli per side (25 X 8-second trains of 40 stimuli).~Sham rTMS: Patients from all four centers randomized to receive sham treatment will undergo the same procedures used in patients receiving active rTMS.
Study NCT04682821 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artificial intelligence assistant system
Description: The intervention is the use of the artificial intelligence assistant system in addition to the common training. The system is an non-invasive AI system which could help the endoscopists to diagnosis and monitor the blind spot during the gastroscope.
Study NCT01390376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAAOI-1
Description: DAAOI-1 1g
Study NCT01390376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAAOI-1
Description: DAAOI-1 2g
Study NCT01390376 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: starch pill
Study NCT04067310 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spray skin protector
Description: Patients will use spray skin protector treatment from the randomization day until the last day of radiotherapy.
Study NCT04067310 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: moisturizer Dnativ Revita derm
Description: Patients will use conventional preventive treatment from the randomization day until the last day of radiotherapy.
Study NCT01393652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05105679
Description: Subjects will receive single ascending doses of PF-05105679 or placebo to investigate safety/tolerability and pharmacokinetics of PF-05105679
Study NCT01393652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-05105679
Description: Subject will be randomized to a treatment sequence, and assigned to placebo, 2 separate single doses of PF-05105679 in the fasted state and to controlled-release Oxycodone 20 mg (positive control) , with at least one week wash-out between doses.
Study NCT02928900 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinician training intervention
Description: This intervention is a clinician training using SP actors to improve communication and empathy skills of HIV care providers who serve HIV-positive adolescents and youth in Kenya.
Study NCT00253747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osmotic-Release Methylphenidate
Description: OROS-MPH dosing strategy will start with 18 mg/day for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). And, nicotine patch dosing schedule will be 21 mg/day during weeks 4-11; 14 mg/day during weeks 12-13; and 7 mg/day in week 14.